Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part A
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. All Subject Population comprised of all participants randomized to treatment who received at least one dose of study treatment. AEs and SAEs were collected from admission until follow-up. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.
Number of Participants With AEs and SAEs-Part B
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. AEs and SAEs were planned to be collected from admission until follow-up.
Number of Participants With AEs and SAEs-Part C
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability/incapacity; is a congenital anomaly/birth defect; other important medical events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before. AEs and SAEs were planned to be collected from admission until follow-up.
Number of Participants With Hematological Parameters of Potential Clinical Importance-Part A
Blood samples were collected for the assessment of hematology parameters. The clinical concern range for the parameters were: hematocrit (high: >0.54 proportion of red blood cells in blood); hemoglobin (high: >180 grams per liter [g/L]), lymphocytes (low: <0.8x10^9 cells per liter [cells/L]); neutrophil count (low: <1.5x10^9 cells/L); platelet count (low: <100x10^9 cells/L and high: >550x10^9 cells/L); white blood cells count (low: <3x10^9 cells/L and high: >20x10^9 cells/L). Data for worst-case post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.
Number of Participants With Hematological Parameters of Potential Clinical Importance-Part B
Blood samples were planned to be collected for the assessment of hematology parameters.
Number of Participants With Hematological Parameters of Potential Clinical Importance-Part C
Blood samples were planned to be collected for the assessment of hematology parameters.
Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part A
Blood samples were collected for the assessment of clinical chemistry parameters. The clinical concern range for the parameters were: albumin (low: <30 millimoles per liter [mmol/L]); alanine aminotransferase (ALT) (high: >=2xupper limit of normal [ULN]); aspartate aminotransferase (AST) (high: >=2xULN); alkaline phosphatase (ALP) (high: >=2xULN); total bilirubin (high: >=1.5xULN); calcium (low: <2 mmol/L and high: >2.75 mmol/L); glucose (low: <3 mmol/L and high: >9 mmol/L); potassium (low: <3 mmol/L and high: >5.5 mmol/L) and sodium (low: <130 mmol/L and high: >150 mmol/L). Data for worst-case post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.
Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part B
Blood samples were planned to be collected for the assessment of clinical chemistry parameters.
Number of Participants With Clinical Chemistry Parameters of Potential Clinical Importance-Part C
Blood samples were planned to be collected for the assessment of clinical chemistry parameters.
Number of Participants With Abnormal Urine Parameters-Part A
Urine samples were taken for the assessment of following urine parameters: specific gravity, potential of hydrogen (pH), glucose, protein, blood and ketones by dipstick method. Microscopic examination was performed and collected for any abnormal dipstick results. Number of participants with abnormal urine parameters any time post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.
Number of Participants With Abnormal Urine Parameters-Part B
Urine samples were planned to be collected for the assessment of urine parameters.
Number of Participants With Abnormal Urine Parameters-Part C
Urine samples were planned to be collected for the assessment of urine parameters.
Number of Participants With Abnormal Electrocardiogram (ECG) Findings-Part A
Triplicate 12-lead ECGs were obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, QT interval corrected using Fridericia's formula (QTcF) and Bazett's QT interval corrected for heart rate (QTcB). ECG measurements were preceded by at least 5 minutes rest for the participant in a semi-recumbent position. Number of participants with abnormal-clinically significant and abnormal-not clinically significant ECG findings at worst case post-Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.
Number of Participants With Abnormal ECG Findings-Part B
Triplicate 12-lead ECGs were planned to be obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, QTcF and QTcB intervals.
Number of Participants With Abnormal ECG Findings-Part C
Triplicate 12-lead ECGs were planned to be obtained using an ECG machine that automatically calculated the heart rate and measured PR, QRS, QT, QTcF and QTcB intervals.
Number of Participants With Abnormal Vital Signs-Part A
Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, respiration rate and temperature were measured in a semi-recumbent position with a completely automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions. Participants are counted in the worst case category that their value changes to (low, normal or high), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the "To Normal or No Change" category. Data for worst case post-Baseline relative to Baseline is presented. Baseline was defined as the latest pre-dose assessment. Placebo arms across similar dosing strategies were combined as pre-specified in reporting and analysis plan.
Number of Participants With Abnormal Vital Signs-Part B
Vital signs including SBP, DBP, heart rate, respiration rate and temperature were planned to be measured in a semi-recumbent position with a completely automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.
Number of Participants With Abnormal Vital Signs-Part C
Vital signs including SBP, DBP, heart rate, respiration rate and temperature were planned to be measured in a semi-recumbent position with a completely automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without distractions.
Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration (AUC[0-t]) for GSK3335065-Part A (Cohorts 1 and 2)
Blood samples for pharmacokinetic (PK) analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. PK Parameter Population comprised of all active participants whose PK sample was obtained and analyzed and who provided PK parameters.
AUC(0-t) for GSK3335065-Part A (Cohorts 3 to 8)
Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
AUC(0-t) for GSK3335065-Part B
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
AUC(0-t) for GSK3335065-Part C (Cohort 13)
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
AUC(0-t) for GSK3335065-Part C (Cohort 14)
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-Inf]) for GSK3335065-Part A (Cohorts 1 and 2)
Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.
AUC(0-Inf) for GSK3335065-Part A (Cohorts 3 to 8)
Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
AUC(0-Inf) for GSK3335065-Part B
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
AUC(0-Inf) for GSK3335065-Part C (Cohort 13)
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
AUC(0-Inf) for GSK3335065-Part C (Cohort 14)
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Time of the Last Measurable Concentration (Tlast) of GSK3335065-Part A (Cohorts 1 and 2)
Blood samples for pharmacokinetic PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
Tlast of GSK3335065-Part A (Cohorts 3 to 8)
Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
Tlast of GSK3335065-Part B
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Tlast of GSK3335065-Part C (Cohort 13)
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Tlast of GSK3335065-Part C (Cohort 14)
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Maximum Observed Concentration (Cmax) of GSK3335065-Part A (Cohorts 1 and 2)
Blood samples for pharmacokinetic PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
Cmax of GSK3335065-Part A (Cohorts 3 to 8)
Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
Cmax of GSK3335065-Part B
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Cmax of GSK3335065-Part C (Cohort 13)
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Cmax of GSK3335065-Part C (Cohort 14)
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Time to Reach Maximum Concentration (Tmax) for GSK3335065-Part A (Cohorts 1 and 2)
Blood samples for pharmacokinetic PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
Tmax of GSK3335065-Part A (Cohorts 3 to 8)
Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
Tmax of GSK3335065-Part B
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Tmax of GSK3335065-Part C (Cohort 13)
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Tmax of GSK3335065-Part C (Cohort 14)
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Clearance for GSK3335065-Part A (Cohorts 1 and 2)
Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.
Clearance for GSK3335065-Part A (Cohorts 3 to 8)
Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
Clearance for GSK3335065-Part B
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Clearance for GSK3335065-Part C (Cohort 13)
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Clearance for GSK3335065-Part C (Cohort 14)
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Volume of Distribution for GSK3335065-Part A (Cohorts 1 and 2)
Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.
Volume of Distribution for GSK3335065-Part A (Cohorts 3 to 8)
Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
Volume of Distribution for GSK3335065-Part B
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Volume of Distribution for GSK3335065-Part C (Cohort 13)
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Volume of Distribution for GSK3335065-Part C (Cohort 14)
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Apparent Terminal Half Life (T1/2) for GSK3335065-Part A (Cohorts 1 and 2)
Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis. Data for Cohort 1 is derived only from time points up to 3 hours as later data in this participant was below limit of quantification.
T1/2 for GSK3335065-Part A (Cohorts 3 to 8)
Blood samples for PK analysis of GSK3335065 were collected at the indicated time points. PK parameters were calculated using standard non-compartmental analysis.
T1/2 for GSK3335065-Part B
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
T1/2 for GSK3335065-Part C (Cohort 13)
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
T1/2 for GSK3335065-Part C (Cohort 14)
Blood samples for PK analysis of GSK3335065 were planned to be collected at the indicated time points.
Change From Baseline in Levels of Tryptophan Metabolites-Part A (Cohort 1 and 2)
Blood samples were collected to measure the kynurenine-3-monooxygenase (KMO) enzyme inhibition by determining the levels of the biomarkers Kynurenine (Kyn) and 3-hydroxykynurenine (3-HK). Baseline was the average of all pre-dose measurements (Day 1 [pre-dose at 1 hour and 30 minutes]). Change from Baseline was calculated as value at the specified time point minus the Baseline value.
Change From Baseline in Levels of Tryptophan Metabolites-Part A (Cohorts 3 to 8)
Blood samples were collected to measure the KMO enzyme inhibition by determining the levels of the biomarkers Kyn and 3-HK. Baseline was the average of all pre-dose measurements (Day -1 [pre-dose at 16 hours, 14 hours, 12 hours and 10 hours] and Day 1 [pre-dose at 30 minutes and 2 hours]). Change from Baseline was calculated as value at the specified time point minus the Baseline value.
Change From Baseline in Levels of Tryptophan Metabolites-Part B
Blood samples were planned to be collected to measure the KMO enzyme inhibition by determining the levels of the biomarkers Kyn and 3-HK.
Change From Baseline in Levels of Tryptophan Metabolites-Part C
Blood samples were planned to be collected to measure the KMO enzyme inhibition by determining the levels of the biomarkers Kyn and 3-HK.